The final results of large-scale clinical trials of the vaccine of the German biotechnology group “CureVac” show that it is 48 percent effective.
Among the participants in the study, “the candidate vaccine showed an overall effectiveness of 48 percent,” Kurwak said.
This result was predictable, given that preliminary results from vaccine tests were published in the middle of last month, which provoked disappointment. This calls into question the possibility of the product becoming the next major after Pfizer, Moderna, AstraZeneca and Jansen in the fight for wider vaccination of the population.
According to Kurwak, the vaccine works better in people between the ages of 18 and 60. With them, it reaches an efficiency of 53 percent. When the vaccine was given to people in this age group, it was 77 percent effective in preventing moderate to severe covid disease and 100 percent effective in preventing hospitalizations and deaths.
From the data available so far, it is not possible to establish in a statistically clear way exactly how effective the vaccine is in people over 60 years of age.
At the end of 2020, the EU has retained up to 405 million doses of Kurlak vaccines, of which 1 million must be delivered to Bulgaria.
–
